Literature DB >> 3881032

Levobunolol vs timolol for open-angle glaucoma and ocular hypertension.

A Cinotti, D Cinotti, W Grant, I Jacobs, M Galin, D Silverstone, D Shin, J Esters, J Lee, R Bouchey.   

Abstract

A group of 162 patients with chronic open-angle glaucoma or ocular hypertension were treated twice daily for up to 15 months with one of the following topical ophthalmic solutions: 0.5% levobunolol, 1% levobunolol, or 0.5% timolol. Overall mean reductions in intraocular pressure were 8 mm Hg for patients receiving 0.5% levobunolol or timolol and 8.2 mm Hg for patients receiving 1% levobunolol. There were no significant differences between levobunolol and timolol in mean reductions in intraocular pressure, percent of patients with adequately controlled intraocular pressure, or life-table estimates of the probability of successful treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881032     DOI: 10.1016/s0002-9394(14)75859-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 2.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

Review 3.  Medical interventions for primary open angle glaucoma and ocular hypertension.

Authors:  C Vass; C Hirn; T Sycha; O Findl; P Bauer; L Schmetterer
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 4.  Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J P Gonzalez; S P Clissold
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

5.  β-blocker eye drops affect ocular surface through β2 adrenoceptor of corneal limbal stem cells.

Authors:  Xingyue Yuan; Xiubin Ma; Lingling Yang; Qingjun Zhou; Ya Li
Journal:  BMC Ophthalmol       Date:  2021-12-05       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.